Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants.  Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Apriori Bio

Sr Engineer II, Data Science

Senior Automation Solutions Data Analyst

Senior Data Specialist, Applied Analytics Solutions

Data Specialist

Intern

Data Analysis Intern

Research Department Intern

Sales Administrator

Principal Scientist

Senior Scientist

Exploratory Scientist

Senior Cell Biologist

Staff Scientist

Graduate Student

Assistant Scientist

Machine Learning Lead

Project Leader, Data Scientist, Senior Staff Scientist

College Research Associate

Co-Director, Chief Technology Officer

Research Associate

Assistant Professor

Assistant Lecturer

PhD Student

Software Engineer

Senior Research Associate

Origination Partner

Founding CEO & Director

Co-founder & CEO

Scientist II, Viral Functional Genomics and Vaccine Design

Investigator I

Researcher

Instructor, Clubes de ciencia

Graduate Student Instructor, Microbiology lab

Instructor, Ethiopia Michigan Platform for Advancing Collaborative Engagement

Doctoral Student

Research Associate II

Virus Isolation and Serology Microbiologist (Microbiologist II)

Lab Control Technician

Manager

Overnight Counselor

Vice President, Strategy & Operations

Co-Founder & Chief Operating Officer

Senior Principal, Origination

Senior Principal, Technology & Strategy

Executive Director, Head of Business Operations & Strategy, Medicinal Sciences

Senior Director, Worldwide R&D Portfolio Strategy

Strategy Lead, BioTherapeutics R&D

Consultant

Bioscience Business Manager

Associate Business Consultant

Scientist

Infectious Disease Fellow

Doctoral Candidate

Teaching Assistant

Mimecast

Outlook

Google Cloud Hosting

Greenhouse.io

Mobile Friendly

Google Tag Manager

VP, Biology

We are unyielding in our pursuit of life-changing therapies and our grit and compassion lead us to fight for a better future for patients and their families. We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.

Kaleido Biosciences

Microsoft Office 365

Remote

Kintai develops novel therapeutics to treat ulcerative colitis, metabolic syndrome, NASH and chronic kidney diseases.

Kintai Therapeutics, Inc.

ElasticEmail

Amazon AWS

Sr Director, Microbiome Sciences

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.For more information, please visit http://www.serestherapeutics.com/ .

Seres Therapeutics

Gmail

Google Apps

WordPress.org

Sr Director, Microbiology

We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Microbiology Scientist â Vaccines

Summer 2024 Intern - Business Intelligence

Sanofi

Amazon CloudFront

Route 53

SendInBlue

Sr Director

Director

Associate Director

McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery. It has a student population of 30,000, and more than 185,000 alumni in 137 countries.

Jeremy Yethon

VP, Biology at Apriori Bio

Jeremy Yethon's Professional Contact Details

Jeremy Yethon's Current Company Details

Apriori Bio

Jeremy Yethon's Work History and Education

Frequently Asked Questions about Jeremy Yethon

What company does Jeremy Yethon work for?

What is Jeremy Yethon's role at Apriori Bio?

What is Jeremy Yethon's email address?

What is Jeremy Yethon's business email address?

What is Jeremy Yethon's direct mobile number?

What industry does Jeremy Yethon work in?

Who are Jeremy Yethon's colleagues?

Colleagues at Apriori Bio

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?